On Monday, Standard BioTools Inc (NASDAQ: LAB) was -5.26% drop from the session before settling in for the closing price of $1.14. A 52-week range for LAB has been $0.99 – $3.04.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 11.99% over the past five years. When this article was written, the company’s average yearly earnings per share was at 65.38%. With a float of $365.09 million, this company’s outstanding shares have now reached $377.53 million.
Let’s look at the performance matrix of the company that is accounted for 818 employees. In terms of profitability, gross margin is 48.31%, operating margin of -100.46%, and the pretax margin is -79.29%.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Standard BioTools Inc stocks. The insider ownership of Standard BioTools Inc is 3.67%, while institutional ownership is 73.82%. The most recent insider transaction that took place on Feb 28 ’25, was worth 5,134,321. In this transaction Director of this company bought 4,820,959 shares at a rate of $1.06, taking the stock ownership to the 58,846,780 shares. Before that another transaction happened on Nov 12 ’24, when Company’s Former Officer proposed sale 57,971 for $2.12, making the entire transaction worth $123,098.
Standard BioTools Inc (LAB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 57.47% during the next five years compared to 11.61% growth over the previous five years of trading.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
You can see what Standard BioTools Inc (LAB) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.09. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.55, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.09 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Standard BioTools Inc (NASDAQ: LAB) saw its 5-day average volume 1.17 million, a negative change from its year-to-date volume of 1.95 million. As of the previous 9 days, the stock’s Stochastic %D was 23.70%. Additionally, its Average True Range was 0.09.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 6.77%, which indicates a significant decrease from 14.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 50.70% in the past 14 days, which was lower than the 87.15% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3183, while its 200-day Moving Average is $1.7610. Nevertheless, the first resistance level for the watch stands at $1.1233 in the near term. At $1.1666, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.2032. If the price goes on to break the first support level at $1.0434, it is likely to go to the next support level at $1.0068. The third support level lies at $0.9635 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are 378,986K outstanding shares of the company, which has a market capitalization of 409.31 million. As of now, sales total 174,430 K while income totals -138,890 K. Its latest quarter income was 46,720 K while its last quarter net income were -34,070 K.
